Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type <i>RAS</i> metastatic colorectal cancer: a meta-analysis.

Onco Targets Ther · 2018 · PMC6065471 · PMID 30100734

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

A nonsignificant trend toward an improved ORR was demonstrated in the wild-type KRAS population with the addition of EGFR inhibitors, and this improvement became more pronounced in the wild-type RAS population, as expected.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.